Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1689-1695. doi: 10.1016/j.dsx.2020.08.031. Epub 2020 Aug 29.
The ABO blood group system is a genetic polymorphism which can affect the clearance of von Willebrand factor. We aimed to assess the levels of newer biomarkers of cardiovascular disease (CVD) risk; pro-oxidant-antioxidant balance (PAB), high sensitivity C-reactive protein (hs-CRP) and anti-heat-shock protein27 (anti-Hsp27) antibody titers in subjects with various blood groups (A, B, AB and O) and with or without traditional CVD risk factors.
The cross-sectional study comprised 6910 subjects. Antigen-antibody agglutination was evaluated by the slide test method for identification of ABO blood groups.
Among three markers, only Serum anti-Hsp27 titers significantly differed between the four blood groups and showed the highest and lowest values in AB and O blood groups (0.26 ± 0.22 and 0.23 ± 0.18 OD, respectively; P < 0.05). Serum anti-Hsp27 was higher in individuals with an AB blood group with metabolic syndrome (MetS), dyslipidemia, hypertension (HTN) and obesity and it was lower in subjects with O blood group; though, two other biomarkers, serum PAB and hs-CRP, were not significantly different between the ABO blood groups. However, they were not different among blood groups in participants with or without diabetes mellitus (DM) (P > 0.05).
Individuals with an AB blood group and high levels of anti-Hsp27 antibody titers may be predisposed to CVDs that can be mediated through the traditional CVD risk factors among middle-aged subjects from northeastern Iran. The fact that differences in anti Hsp27 are only found in the subgroup with other risk factors suggest that the difference between ABO blood groups is a consequence rather than a cause.
ABO 血型系统是一种遗传多态性，可影响血管性血友病因子的清除。我们旨在评估心血管疾病（CVD）风险的新型生物标志物水平；在具有各种血型（A、B、AB 和 O）和具有或不具有传统 CVD 危险因素的个体中，评估促氧化剂-抗氧化剂平衡（PAB）、高敏 C 反应蛋白（hs-CRP）和抗热休克蛋白 27（anti-Hsp27）抗体滴度。
本横断面研究包括 6910 名受试者。通过玻片试验法评估抗原抗体凝集，以鉴定 ABO 血型。
在三种标志物中，只有血清抗 HSP27 滴度在四组血型之间存在显著差异，AB 和 O 血型的滴度最高和最低（分别为 0.26±0.22 和 0.23±0.18 OD；P<0.05）。AB 血型个体的代谢综合征（MetS）、血脂异常、高血压（HTN）和肥胖患者的血清抗 HSP27 较高，O 血型个体的血清抗 HSP27 较低；然而，其他两种生物标志物，血清 PAB 和 hs-CRP，在 ABO 血型之间无显著差异。然而，在伴有或不伴有糖尿病（DM）的个体中，它们在各组之间没有差异（P>0.05）。
AB 血型个体和高水平抗 HSP27 抗体滴度可能易患 CVD，这可以通过伊朗东北部中年人群的传统 CVD 危险因素介导。只有在具有其他危险因素的亚组中才发现抗 HSP27 的差异，这表明 ABO 血型之间的差异是结果而不是原因。
